BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37803333)

  • 21. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
    Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
    J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 29. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
    Xu H; Jin J; Chen Y; Wu G; Zhu H; Wang Q; Wang J; Li S; Grigore FN; Ma J; Chen CC; Lan Q; Li M
    Oncogene; 2022 Jul; 41(31):3876-3885. PubMed ID: 35780181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-200c-based metabolic modulation in glioblastoma cells as a strategy to overcome tumor chemoresistance.
    Cardoso AM; Morais CM; Sousa M; Rebelo O; Tão H; Barbosa M; Pedroso de Lima MC; Jurado AS
    Hum Mol Genet; 2021 Nov; 30(23):2315-2331. PubMed ID: 34245265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.
    Su YK; Lin JW; Shih JW; Chuang HY; Fong IH; Yeh CT; Lin CM
    Cells; 2020 Aug; 9(8):. PubMed ID: 32784466
    [No Abstract]   [Full Text] [Related]  

  • 34. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
    Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
    J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
    Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M
    Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells.
    Haryuni RD; Tanaka T; Takahashi JI; Onuma I; Zhou Y; Yokoyama S; Sakurai H
    Biol Pharm Bull; 2021; 44(11):1681-1687. PubMed ID: 34719645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation.
    Xu HB; Chen XZ; Yu ZL; Xue F
    J Ethnopharmacol; 2023 Jan; 301():115855. PubMed ID: 36280019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
    Stéphanou A; Ballesta A
    Pharmacol Res Perspect; 2019 Feb; 7(1):e00454. PubMed ID: 30705757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.